Extracorporeal photochemotherapy for graft versus host disease in pediatric patients.
Although worldwide experience with extracorporeal photochemotherapy (ECP) for GvHD treatment has grown enormously over the past decade, only a few pediatric centers have experience with ECP. Studies reporting clinical outcome in children with GvHD treated by ECP comprises a very limited number of patients with only few information described. This review article remain focused on the efficacy and the safety aspect of ECP in pediatric patients to provide information about the steps that should be taken to overcome the difficulties with ECP use in children with GvHD. Data concerning 19 children with acute GvHD and 54 children with chronic GvHD treated with ECP and reported so far have been considered. The principal reasons for the restriction in the use of ECP in children such as: (1) technical difficulties of leukapheresis procedures (venous access, hemodynamic, metabolic and hematological tolerance); and (2) the necessity of a specially adapted pediatric patient approach to improve the psychological tolerance of this treatment are discussed. The data of this retrospective review demonstrate that ECP is beneficial and well tolerated in children with GvHD. It can be safely used even in young children with low body weight and a poor performance status when it was performed by a qualified pediatric team. The observations concerning the response rate and onset suggest that in children with acute GvHD, ECP should be started early in the course of disease and employed over a relatively short period of time. As far as chronic GvHD is concerned, despite the fact that it is preferable to begin ECP early as second line therapy, it may also be beneficial in patients with late-stage disease.
Kanold
Justyna
J
Unité Bioclinique de Thérapie Cellulaire, Service d'Hématologie et d'Oncologie Pédiatrique, Hôtel Dieu, CHU, BP69, 11, Boulevard Léon Malfreyt 63003 Clermont-Ferrand, France. jkanold@chu-clermontferrand.fr
Paillard
Catherine
C
Halle
Pascale
P
D'Incan
Michel
M
Bordigoni
Pierre
P
Deméocq
François
F
D001781:Blood Component Removal / Q000379:methods; D002404:Catheterization / Q000009:adverse effects; D002648:Child; D000075202:Contraindications; D006086:Graft vs Host Disease / Q000628:therapy*; D006801:Humans; D017893:Photopheresis / Q000009:adverse effects / Q000379:methods; D016896:Treatment Outcome